# Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

> **NCT05219318** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Bordeaux** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

## Interventions

- **DRUG:** Combination PD-1/PD-L1 ICI + VEGFR-TKI
- **OTHER:** Treatment pause

## Key facts

- **NCT ID:** NCT05219318
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-23
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05219318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05219318, "Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05219318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*